NCT01552395已完成不适用
A Prospective Safety Study in 24 Months Treatment of Nocturia With Minirin Melt in Clinical Practice in the Czech Republic
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,136
- 试验地点
- 67
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
A Confirmation of the Safety Profile for Minirin Melt in Clinical Practice
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •habitual or psychogenic polydipsia,
- •known or suspected cardiac insufficiency
- •other conditions requiring treatment with diuretics
- •moderate and severe renal insufficiency
- •known hyponatremia
- •syndrome of inappropriate ADH secretion
结局指标
主要结局
Number of patients with adverse events
时间窗: 24 months
次要结局
- Number of changes in dosage regime(24 months)
研究者
研究点 (67)
Loading locations...
相似试验
已完成
不适用
A Study of Minirin Melt in Patients With NocturiaNocturiaNCT01212224Ferring Pharmaceuticals2,187
已完成
不适用
A Study of Minirin Melt in Patients With NocturiaNocturiaNCT01222598Ferring Pharmaceuticals588
已完成
不适用
Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced VasospasmCerebral VasospasmSubarachnoid HemorrhageNCT03517670Nantes University Hospital60
终止
不适用
Study of Minirin Melt® in Adult Patients With NocturiaNocturiaNCT03089073Ferring Pharmaceuticals835
Unknown
4 期
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIKMyopiaHyperopiaPresbyopiaNCT01977807Technolas Perfect Vision GmbH100